Know Cancer

or
forgot password

PET-MR Fusion Imaging and Surrogate Marker for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients


N/A
18 Years
70 Years
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

PET-MR Fusion Imaging and Surrogate Marker for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients


Inclusion Criteria:



- Pathologically confirmed breast cancer

- Clinical stage IIb, IIIa, IIIb, IIIc

- Must have measurable disease

- Performance status of ECOG 0-2

- Adequate, bone marrow, liver, heart, and renal function

- Who did not receive chemotherapy for breast cancer

- Must agree with and signed informed consent

Exclusion Criteria:

- Prior history of cancer besides breast cancer

- Active bacterial infection

- Pregnant or lactating women

- Psychological disease or seizure

- History of arrhythmia, congestive heart failure, myocardial infarct, or unstable
angina

- Male breast cancer

- Who had a pacemaker or history of open heart surgery

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Change in the maximum dimension of the tumor over time

Outcome Time Frame:

baseline, completion of 1st cycle of chemotherapy, and completion of 6th cycle of chemotherapy

Safety Issue:

No

Principal Investigator

Woo Kyung Moon, M.D., Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department of Radiology, Seoul National University Hospital

Authority:

Korea: Ministry for Health, Welfare and Family Affairs

Study ID:

PET-MR Breast Cancer

NCT ID:

NCT01190566

Start Date:

May 2010

Completion Date:

March 2012

Related Keywords:

  • Breast Cancer
  • Magnetic Resonance Imaging, Functional
  • Tomography, Positron-Emission
  • chemotherapy
  • Breast Neoplasms

Name

Location